Brief: MediciNova Announces Positive Results From Secondary Analysis Of Phase 2 Trial Of MN-166 Published In The American Journal Of Drug And Alcohol Abuse
05/12/2022 23:13
Dec 5 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA ANNOUNCES POSITIVE RESULTS FROM SECONDARY
ANALYSIS OF
PHASE 2 TRIAL OF MN-166 (IBUDILAST) PUBLISHED IN THE AMERICAN
JOURNAL OF DRUG AND ALCOHOL ABUSE
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake